Investments, Funding & Disinvestment

Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.

Health Minister Khaled Abdel Ghaffar discussed the proposed fund and potential areas of cooperation with representatives of Gold Rock Venture during a meeting at the ministry’s headquarters in New Alamein.

The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.

The initiative supports Abu Dhabi’s broader strategy to use digital health technologies, real-world evidence and artificial intelligence to advance preventive and personalised healthcare.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.

AsymBio plans to use the additional capital to expand its research and development capabilities, GMP manufacturing lines and high-containment facilities.

Through its collaboration with Al Borg Diagnostics, members can schedule laboratory tests at home, reducing the need to visit healthcare facilities while encouraging earlier diagnosis and routine health monitoring.

Under the collaboration, Chugai scientists will use Biomni Lab to bring together AI capabilities and diverse biomedical resources within the company’s research environment.

Alteogen designed Hybrozyme to help convert biologic medicines that are traditionally administered through intravenous infusion into subcutaneous formulations.

The newly raised capital will enable Inocras to expand its commercial operations and clinical infrastructure across the United States.